JF
SGMT icon

Jump Financial’s Sagimet Biosciences SGMT Stock Holding History

Jump Financial’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,951
Closed -$151K – 2420
2026
Q1 		$151K Buy
+28,951
New +$161K ﹤0.01% 1715
2025
Q3 		– Sell
-148,351
Closed -$1.13M – 2186
2025
Q2 		$1.13M Buy
+148,351
New +$626K 0.01% 932

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jump Financial's SGMT Position: Q2 2026 in Review

Jump Financial sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 28,951 shares — an estimated $151K sold.

Jump Financial first reported a position in SGMT in Q2 2025 and held it in 2 quarters. The position peaked at $1.13M in Q2 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Jump Financial reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 28,951 Sagimet Biosciences shares in Q2 2026, an estimated $151K.
  • Jump Financial first reported a position in Sagimet Biosciences in Q2 2025 and held it in 2 quarters.
  • Jump Financial's Sagimet Biosciences position peaked at $1.13M in Q2 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.